

**ASX Release****Oventus signs agreement with Careica Health, Canada****Key highlights:**

- **New contract for provision of Oventus Sleep Treatment Platform executed with Careica Health, a leading provider of respiratory services in western Canada**
- **Patients to be referred from 26 locations across the Careica network to an initial four Lab in Lab sites**
- **Oventus technology to be offered to CPAP-intolerant individuals via extension to Careica's well known SLEEP program**
- **New agreement takes total locations contracted under Oventus' Lab in Lab model to 49**

Brisbane, Australia 18 May 2020: Obstructive Sleep Apnoea (OSA) treatment innovator, Oventus Medical Ltd (ASX: OVN) is pleased to announce that it has signed an agreement with Careica Health, one of western Canada's largest privately-owned providers of diagnostics and treatment for obstructive sleep apnoea and home oxygen services.

Under the agreement, patients will be referred from Careica's 26 homecare locations which span the provinces of Manitoba, Saskatchewan, Alberta, and British Columbia to an initial four sites which will operate the Oventus Lab in Lab business model. The agreement extends Careica's well known SLEEP program which will now include Oventus' O2Vent oral appliance therapy as an alternative for CPAP-intolerant individuals.

Cory McArthur, Careica's President and CEO commented, "We are excited about the partnership with Oventus as we believe there is considerable opportunity for not only a Lab in Lab model, but also to extend our SLEEP program to include dental sleep treatment. The precise way in which O2Vent Optima devices fit patients means we expect a very low number of product adjustment requests which should enable smooth and efficient delivery of the product under our telemedicine offering for patients."

Dr Chris Hart, founder and CEO of Oventus commented, "Careica has been operating a successful respiratory business for more than 20 years. Oventus is proud that such a well-respected Canadian sleep group has chosen to augment their existing sleep offering by adopting our treatment platform. As COVID-19 restrictions start to lift in Canada, we currently expect to see the four Lab in Lab sites deployed by mid June."

Once fully deployed, each location expects to order a minimum of 20 O2Vent Optima devices per month. The agreement has a term of three years, with an automatic three year renewal, unless a party elects not to renew no later than 180 days prior to the end of the three year

period. These recent agreements take the total number of locations contracted under Oventus' Lab in Lab model to 49.

—ENDS—

For further information, please visit our website at [www.o2vent.com](http://www.o2vent.com) or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496 or [investors@oventus.com.au](mailto:investors@oventus.com.au)

Jane Lowe, IR Department: M: +61 411 117 774 or [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

**About Oventus – see more at [www.o2vent.com](http://www.o2vent.com)**

Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for sleep apnoea and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients' access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances, Oventus O2Vent devices manage the entire upper airway via a unique and patented built-in airway. O2Vent devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The O2Vent allows nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airway integrated in the appliance.

The ExVent™ is a valve accessory that fits into the open airway of the O2Vent Optima device, to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea<sup>1</sup>.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnea, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnea treatment<sup>3</sup>. The O2Vent Optima and ExVent provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

<sup>1</sup> Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

<sup>2</sup> Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

<sup>3</sup> Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.